MYGN Forex ziņas

Myriad Genetics Slashes FY22 Outlook As Q3 Results Miss Estimates; Stock Down 8%

While reporting financial results for the third quarter on Tuesday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings and revenue guidance for the full year 2022 to reflect third quarter business updates.

RTTNews | 813 days ago

Myriad Genetics Trims FY22 Profit Outlook, But Q2 Results Top Estimates

While reporting financial results for the second quarter on Thursday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings guidance for the full year 2022, while maintaining annual revenue outlook.

RTTNews | 902 days ago

Noteikumi | Privātums | Lapas karte | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.04022	GBPUSD	1.23076	AUDUSD	0.62755
USDJPY	156.517	USDCAD	1.43879	USDCHF	0.90661